ESTRO 2024 - Abstract Book

S2308

Clinical - Urology

ESTRO 2024

Conclusion:

EMBARK trial criteria identify high-risk nmCSPC patients who may benefit from enzalutamide-based therapies providing valuable insights into the application of these treatments. Our real-world data analysis confirms results consistent with the EMBARK trial population, identifying the need to optimize patient treatments in this clinical setting.

Keywords: Prostate, recurrence, biochemical

References:

Freedland SJ, De Giorgi U, Gleave M, et al. A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design. BMJ Open 2021;11:e046588. doi:10.1136/ bmjopen-2020-046588

277

Proffered Paper

Adjuvant EBRT for muscle-invasive bladder cancer: phase 2 trial secondary analysis (NCT02397434)

Flor Verghote 1,2 , Piet Dirix 3 , Charles Van Praet 2,4 , Charlien Berghen 5 , Ben Vanneste 1,2 , Sara Junius 6 , Nick Liefhooghe 7 , Leen Noé 8 , Gert De Meerleer 5 , Piet Ost 2,3 , Valérie Fonteyne 1,2 1 Ghent University Hospital, Radiotherapy-Oncology, Ghent, Belgium. 2 Ghent University, Human structure and Repair, Ghent, Belgium. 3 Iridium Network, Radiation-Oncology, Antwerp, Belgium. 4 Ghent University Hospital, Urology,